RAPP Rapport Therapeutics
Rapport Therapeutics earnings company data as of 7:50 PM ET 10/23
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by RAPP's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $1.7M bought by 6 insiders
- None no sales outside a trading plan
- $46.9M sold by 5 insiders under 10b5-1 plans
-
Abraham Ceesay CEOPlanned sale$64K 2,210 shares at $29.16 0.5% of stakeTraded Oct 21 Filed Oct 23
-
Ramiro Sanchez DirectorBuy$98K 3,600 shares at $27.35 New stakeTraded Oct 23 Filed Oct 23
-
Paul M Silva DirectorBuy$100K 3,680 shares at $27.08 New stakeTraded Oct 22 Filed Oct 22
-
Wendy B. Young DirectorBuy$100K 3,789 shares at $26.39 +40% to stakeTraded Oct 22 Filed Oct 22
-
Steven M Paul DirectorBuy$974K 35,714 shares at $27.28 +86% to stakeTraded Oct 22 Filed Oct 22
-
John Maraganore DirectorBuy$249K 9,411 shares at $26.45 New stakeTraded Oct 22 Filed Oct 22
-
Troy A. Ignelzi CFOBuy$144K 5,500 shares at $26.10 +55% to stakeTraded Oct 21 Filed Oct 21
-
Abraham Ceesay CEOPlanned sale$143K 4,522 shares at $31.68 1% of stakeTraded Oct 6–7 Filed Oct 8
-
Cheryl Gault COOPlanned sale$332K 10,000 shares at $33.19 6.7% of stakeTraded Sep 30 Filed Oct 1
-
Abraham Ceesay CEOPlanned sale$87K 2,210 shares at $39.17 0.5% of stakeTraded Sep 23 Filed Sep 24
-
Abraham Ceesay CEOPlanned sale$374K 8,210 shares at $45.61 1.8% of stakeTraded Sep 8 Filed Sep 9
-
Abraham Ceesay CEOPlanned sale$938K 18,921 shares at $49.57 3.9% of stakeTraded Aug 25 Filed Aug 26
-
Krishnaswamy Yeleswaram Chief Development OfficerPlanned sale$2.5M 50,160 shares at $50.47 20% of stakeTraded Aug 24–25 Filed Aug 26
-
Krishnaswamy Yeleswaram Chief Development OfficerPlanned sale$20K 404 shares at $49.90 0.2% of stakeTraded Aug 19 Filed Aug 20
-
Abraham Ceesay CEOPlanned sale$2.4M 51,499 shares at $47.25 9.6% of stakeTraded Aug 10–11 Filed Aug 12
Also filed in the last 12 months, not counted as buying or selling: 3 sales to cover taxes, 2 stock grants, and 2 option exercises.
SEC filings
Recent issuer filings from EDGAR, 10 shown.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.